Free Trial
→ White House to reset Social Security? (From Altimetry) (Ad)
NASDAQ:SNSE

Sensei Biotherapeutics Q3 2023 Earnings Report

Sensei Biotherapeutics logo
$7.66 +0.18 (+2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$7.26 -0.40 (-5.22%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Sensei Biotherapeutics EPS Results

Actual EPS
-$5.60
Consensus EPS
-$5.60
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sensei Biotherapeutics Announcement Details

Quarter
Q3 2023
Date
11/7/2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Sensei Biotherapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Friday, August 1, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Sensei Biotherapeutics' Q3 2023 Press ReleasePress Release
(8-K)
Sensei Biotherapeutics' Q3 2023 Quarterly reportQuarterly report
(10-Q)

Sensei Biotherapeutics Earnings Headlines

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
June 13, 2025 | globenewswire.com
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
May 6, 2025 | globenewswire.com
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
June 20, 2025 | Altimetry (Ad)
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
April 2, 2025 | globenewswire.com
Sensei Biotherapeutics announces initial results from solnerstotug trial portion
March 29, 2025 | markets.businessinsider.com
Sensei Rockets on FY ’24 Results
March 29, 2025 | baystreet.ca
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:SNSE), an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

View Sensei Biotherapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles